Health economic evaluations have recently become an important part of the clinical and medical research process and have built upon more advanced statistical decision-theoretic foundations. In some contexts, it is officially required that uncertainty about both parameters and observable variables be properly taken into account, increasingly often by means of Bayesian methods. Among these, probabilistic sensitivity analysis has assumed a predominant role. The objective of this article is to review the problem of health economic assessment from the standpoint of Bayesian statistical decision theory with particular attention to the philosophy underlying the procedures for sensitivity analysis.
Introduction
In recent years, health economics has become an increasingly important discipline in medical research, especially with the transition from the paradigm of evidence-based medicine to that of translational research, 1,2 which aims at making basic research applicable in the context of real practice, and under budget constraints, in order to enhance patients' access to optimal health care.
Since the late 1970s, methods like cost-effectiveness and cost-utility analysis have been established in the health care arena, especially in the Anglo-Saxon world. 3 Moreover, in the past 10 years, health economic evaluations have built on more advanced statistical decision-theoretic foundations, effectively becoming a branch of applied statistics, 4, 5 increasingly often under a Bayesian statistical approach. [6] [7] [8] [9] [10] Even though the process is, technically, a simple application of standard decision-theoretic precepts, 11 health economics is complicated by issues related to other important factors that play a major role in real practice medical decision making. Among these are the difficulty of applying standard cost-effectiveness techniques in the regulatory process, 12 and the necessity of properly accounting for uncertainty in the decision process, an issue known as sensitivity analysis. 8 This latter in particular is fundamental: in some drug control regimes -for example, NICE (a glossary of all abbreviations/acronyms is provided at the end of the paper) in the UK 13 -it is a required basic component of any new drug approval or reimbursement dossier.
The objective of this article is to review the problem of health economic assessment from the standpoint of Bayesian statistical decision theory, with specific attention to the basic statistical framework and the philosophy underlying the procedures for sensitivity analysis. In particular, in line with recent contributions to the literature, we advocate the use of an integrated vision based on value-of-information (VI) analysis, a procedure grounded in the theory of decision under uncertainty, and criticise the indiscriminate use of other approaches to sensitivity analysis.
Statistical framework
In a typical health economic problem, we are interested in the management of a particular clinical condition for which a set of interventions t 2 T ¼ (0, 1,. . ., T) is available. We can apply a generic intervention t to any unit i in the relevant population and observe a (possibly multivariate) response, Y i . Typically, Y i will be represented by a suitable clinical outcome (e.g. blood pressure or occurrence of myocardial infarction), together with a measure of the costs associated with the given intervention.
The unit i might itself be a population, and the treatment t some population-level policy intervention. Sometimes, though not always, the relevant population-level response Y i would be an average, or other summary (e.g. mean death rate or median time to onset of a disease) of individual-level responses within that population.
The objective of the health economic evaluation is to decide which treatment to apply to a new unit i 0 , judged as similar to, or, in statistical terms, exchangeable 14 with all the others receiving the same treatment.
Example
We consider a health economic problem, which we use throughout the paper as a motivating example to discuss the rationale behind health economic modelling. We switch between theoretical considerations and the example to show the practical implications. The example is based on a real health economic model. 15 Suppose the interest is in an infectious disease, for instance influenza, for which a new vaccine has been produced. Under the current management of the disease some individuals treat the infection by taking over the counter (OTC) medications. Some subjects visit their GP and, depending on the gravity of the infection, may receive treatment with antiviral drugs, which usually cures the infection. However, in some cases complications may occur. Minor complications will need a second GP visit after which the patients become more likely to receive antiviral treatment. Major complications are represented by pneumonia and can result in hospitalisation and possibly death. In this scenario, the costs generated by the management of the disease are represented by OTC medications, GP visits, the prescription of antiviral drugs, hospital episodes and indirect costs such as time off work.
The focus is on the clinical and economic evaluation of the policy that makes the vaccine available to those who wish to use it (t ¼ 1) against the null option (t ¼ 0) under which the vaccine will remain unavailable.
We note here that our purpose is in reviewing the statistical methodology and so our results should not be taken as contributing in any way to guidance as to an appropriate management of the disease under discussion: we refer to other publications for a detailed discussion of both the clinical and economic issues. [15] [16] [17] [18] 
Modelling
The assumption of exchangeability essentially amounts to assuming the following data-generating process for the observables Y i . First, we introduce a population parameter h, generally involving treatment specific components: h ¼ ( 0 ,. . ., t ,. . ., T ). Current uncertainty about h is formally described by a suitable probability distribution. This is computed starting from a (possibly subjective) prior distribution that describes the state of science about the parameters before observing any new data. For example, for each possible intervention t, patient-level data will generally be available (as produced by a set of randomised trials or observational studies) in the form D t ¼ {y i : i ¼ 1,. . ., n t }. We generally refer to the whole set of background information as
The joint distribution of all the parameters is then p(h | D), from which it is possible to obtain every single marginal distribution p( t | D).
Conditionally on h and a proposed treatment t, the second step of the data generation process consists in drawing the Y i 's independently from the probability distribution p(y | t ), which describes the individual variability of the future (yet unobserved) health economic response. A similar general framework has been described in the health economic literature. 6 
Example (continued)
We describe here the model used for the vaccine problem. In a population made up of N individuals, we model V 1 , the number of patients taking up the vaccine when available, using a Binomial(N, ) distribution, depending on the vaccine coverage rate . Obviously, V 0 ¼ 0 as the vaccine is not available in the status quo. For convenience, we denote the total number of patients in the two groups, vaccinated (v ¼ 1) and non-vaccinated (v ¼ 0), by n tv with n t1 9 V t and n t0 9 N À V t , respectively.
Let the relevant clinical outcomes be defined as j ¼ 1: influenza infection; j ¼ 2: GP visit; j ¼ 3: minor complications; j ¼ 4: major complications; j ¼ 5: hospitalisation; j ¼ 6: death; and j ¼ 7: adverse events of influenza vaccination. For each clinical outcome j, let j be its baseline rate of occurrence and let v be the proportional reduction in the chance of infection due to the vaccine. Vaccinated patients (the group v ¼ 1) will experience a reduction in the chance of infection by a factor 1 ; conversely, for v ¼ 0, individuals are not vaccinated and so the chance of infection is just the attack rate 1 . This is equivalent to setting 0 9 0.
Under these assumptions, the number I tv of individuals becoming infected in each group can be modelled using a Binomial(n tv , v ) distribution, where v 9 1 (1 À v ) is the probability of infection. Among the infected subjects, the number visiting a GP for the first time is modelled as GP ð1Þ tv $ BinomialðI tv , 2 Þ. Using a similar reasoning, among those who have had a GP visit, we can define: the number of individuals with minor complications GP ð2Þ tv $ BinomialðGP ð1Þ tv , 3 Þ; the number of those with major complications P tv $ BinomialðGP ð1Þ tv , 4 Þ; the number of hospitalisations H tv $ BinomialðGP ð1Þ tv , 5 Þ; and the deaths D tv $ BinomialðGP ð1Þ tv , 6 Þ. The number of individuals experiencing adverse events due to vaccination is computed as AE tv $ Binomial(n tv , 7 )obviously, this will be identically 0 in the status quo (t ¼ 0) and among those individuals who choose not to take the vaccine up in the vaccination scenario (t ¼ 1, v ¼ 0).
We also include in the model suitable parameters to describe the remaining aspects of the clinical pathway described in Section 2.1, such as the chance of receiving a prescription after the first GP visit ( 1 ) or following minor complications ( 2 ) for a number of antiviral drugs (); of taking OTC medications (); and of remaining off-work () for a number of days (). Combining these with the relevant populations at risk, we can then derive the expected number of individuals experiencing each of these events.
As for the costs, following the specification of the actual case 15 on which we base our evaluation, we consider the relevant resources as h ¼ 1: GP visits; h ¼ 2: hospital episodes; h ¼ 3: vaccination; h ¼ 4: time to receive vaccination; h ¼ 5: days off work; h ¼ 6: antiviral drugs; h ¼ 7: OTC medications; h ¼ 8: travel to receive vaccination. For each, we define h to represent the associated unit cost for which we assume a suitable lognormal distribution, a convenient choice to model positive, continuous variables such as costs.
Finally, we include in the model suitable parameters to represent the loss in quality of life generated by the occurrence of the clinical outcomes. Estimations for the various clinical outcomes can be difficult to obtain. Nevertheless, it is possible to use validated instruments (like the EQ-5D 19 ) to estimate the Quality Adjusted Life Years (QALYs 20 ), a combined measure of quantity and quality of life used to determine the number of extra years that would be added by an intervention. Let ! j represent the QALYs lost when an individual experiences the jth outcome. We assume that GP visits do not generate loss in QALYs and therefore set ! 2 ¼ ! 3 9 0; the remaining ! j 's are modelled using a suitable lognormal distribution.
With respect to the discussion of Section 2.2, the assumptions encoded by this model are that we consider a population parameter h ¼ ( 0 , 1 ), with the two components being defined as 0 ¼ ( j , 1 , 2 , , , , , h , ! j ) and 1 ¼ (, j , v , 1 , 2 , , , , , h , ! j ). We assume that the components of h have the distributions specified in Table 1 .
The distributions of Table 1 are derived using suitable 'hyper-parameters' that have been set to encode knowledge D available from previous studies and expert opinion (the relevant sources used to derive values that are consistent with real clinical practice are described elsewhere 15 ). For example, a Beta distribution with hyper-parameters a ¼ 13.01 and b ¼ 172.38 has the property of having a mean value of approximately 0.069 and contains 95% of the probability mass in the interval [0.004 À 0.115], which is what is suggested by existing data on influenza incidence. It is therefore possible to encode the prior knowledge on 1 using such a distributional assumption.
We note, however, that the choice of the prior distributions is a matter of context knowledge; for instance, parameters representing the probability of occurrence of an event, e.g. the vaccine attack rate , can (but do not have to) be modelled using a Beta distribution. This is just a mathematical convenience, and in fact, it is possible to use different functions to describe the existing knowledge. 21 In practice, however, relatively 'standard' choices can be applied to reasonably approximate the prior information.
Conditionally on the relevant elements of h, the observed health economic response is represented by Y ¼ ðV t , I tv , GP ð1Þ tv , GP ð2Þ tv , P tv , H tv , D tv , AE tv Þ. Its joint distribution is specified using the formulation described above and its components can be combined to implement the economic analysis.
Decision making in health economics
Suppose an intervention t is applied and results in outcome y. In health economic terms, we can quantify this situation by a combination of a measure of clinical effectiveness e (for instance measured in terms of QALYs) of the outcome y, and the costs c associated with the selected intervention t. With each situation (y, t), we thus associate a pair (e, c). The objective of health economic evaluations is to compare the proposed interventions in terms of their expected performances along these two dimensions of interest, benefit and cost. For example, we might consider the increment in mean effectiveness: Á e :¼ E½e j 1 À E½e j 0 and the increment in mean cost:
(note that these are functions of the unknown quantities 0 , 1 and as such are random variables).
Historically, health economic evaluations have been concerned with the calculation of the Incremental Cost Effectiveness Ratio (ICER), defined as ICER 9 E[Á c ]/E[Á e ], where the expectations are now over the subjective distribution of h.
The ICER, a pure number, represents the cost per incremental unit of effectiveness (e.g. cost per QALY gained, or cost per death/event averted). The use of the ICER has been widely criticised because of some major limitations. 10 For example, knowing the sign of the ICER is not sufficient to identify the optimal treatment: an ICER of 100 can be derived by values of (E[Á e ], E[Á c ]) ¼ (2, 200) , indicating that the new treatment produces an increase in effectiveness of 2 units at the A more effective way of describing the problem of allocating the best treatment to the new unit i 0 is to use the formal theory of decision making under uncertainty, which is in this case generated by the imperfect knowledge of the random quantities (Y, h). 8, 22 We take the standpoint of a body that is responsible for issuing guidance on the implementation of alternative interventions for specific public health matters. As suggested earlier, typically, a standard programme will be available and a new one is suggested to replace it, perhaps partially or only on specific sub-populations of individuals. The argument can easily be extended to T > 2 different treatments; however, for the sake of simplicity, we here confine attention to the case T ¼ (0, 1).
The overall value of applying treatment t and obtaining response y is supposed measured by a utility function u(y, t), assigning a numeric value to each combination of outcomes and costs. According to the precepts of Bayesian decision theory and on the basis of the current data D, the value of taking decision t is the expected utility,
The expected utility is obtained by averaging over the uncertainty in both population ('objective') and parameters ('subjective') domains. The overall utility is U * 9 max t U t , based on choosing the intervention t yielding this maximum value. Equivalently, we choose t ¼ 1 if (and, henceforth ignoring ties, only if) EIB > 0, where
is the expected incremental benefit (of treatment 1 over treatment 0). It is easy to see that
Note that EIB is a fixed quantity, uncertainty in both domains having been averaged out. The Bayesian process thereby provides a ranking of the alternatives.
Choosing a utility function: the net benefit
The main difficulty in applying decision theory and (1) is that a form of the utility function must be specified. In a health economic problem, we need to combine the two measures e and c into a single real-valued utility measure, u(y, t) ¼ f(e, c). While there are many possibilities, a common form of utility function is the (monetary) net benefit 23 uð y, tÞ ¼ ke À c:
Here k is a 'willingness-to-pay' parameter used to put cost and benefits on the same scale and represents the budget that the decision maker is willing to invest to increase the benefits by one unit.
The main advantage of the net benefit over other possible forms of utility function (and the main reason for its widespread use) is that it has a fixed form, once the variables (e, c) are defined. Moreover, the net benefit is linear in (e, c), which makes for a simple interpretation and easy calculations. Nevertheless, the use of the net benefit presupposes that the decision maker is risk neutral, which is by no means always appropriate in health policy problems. 24 We consider this in more details in Section 7.
When the net benefit is used as utility function, cost-effectiveness analysis focuses on
where the expectations are now over the subjective distribution of h.
Example (continued)
In order to perform the economic analysis, we need to define suitable measures of cost and effectiveness. The total cost associated with each clinical resource can be computed by multiplying the unit cost h by the number of patients consuming it. For instance, the overall cost of GP visit is GP ð1Þ tv þ GP ð2Þ tv Â 1 . If we indicate with N tvh the total number of individuals consuming the hth resource under intervention t and in group v, we can then extend this reasoning and compute the average population cost under intervention t as
Similarly, the total QALYs lost due to the occurrence of the relevant outcomes can be obtained by multiplying the number of individuals experiencing them by the weights ! j . For example, the total number of QALYs lost to influenza infection can be computed as I tv Â ! 1 . If we let M tvj indicate the number of subjects with the jth outcome in intervention t and group v, we can define the population average measure of effectiveness for intervention t as
We ran the model described in Section 2.3 using a MCMC approach (R and WinBUGS/JAGS codes for the statistical and economic analysis are available from the authors on request). Using the results obtained by 1000 simulations of the model after convergence to the posterior distribution has been assessed, we can compute the expected utility U t , based on the net benefit as utility function for each value of the willingness-to-pay parameter k 2 [0 À 50 000]. This is then used to identify the optimal intervention.
Since it is likely that the decision maker is not certain about the value of the willingness-to-pay that they are likely to select in a given problem, the analysis is typically performed (and reported) on a grid of reasonable k values as shown in Figure 1 , which depicts the EIB for the comparison between vaccination and the status quo.
From the graph, we can identify the break even point, i.e. the value of k for which the optimal decision is modified. In this case, for k k * ¼ 20 100, EIB < 0 and therefore maintaining the status quo is the optimal decision. Conversely, for all k > k * vaccination is the most cost-effective strategy. The value of the break even point corresponds to the ICER and quantifies the point in which the decision maker is indifferent between the two options.
For the sake of simplicity, we can also select for definiteness a threshold value of k ¼ 25 000 (usually suggested by NICE as the reference cost-per-QALY) and replicate the analysis assuming that this is the value used by the decision maker. If the decision maker were willing to set this particular value of k as the budget to allocate for the treatment of the disease under analysis, the EIB for t ¼ 1 vs t ¼ 0 would be 1.23. Vaccination would therefore prove the most cost effective intervention and it should be then selected to replace the status quo.
Uncertainty in the decision process
The above analysis shows how, in the Bayesian approach, both individual variations and uncertainty in the value of the parameters are averaged out. From the decision-theoretic point of view, identification of the overall expected utility is all that is needed to reach the best decision given the current state of knowledge available to the decision maker. This point has been argued in the context of health economics. 25 However, implementing an intervention is typically associated with some risks such as the irreversibility of investments, and therefore medical decision making can be viewed as a two-stage Figure 1 . Analysis of the expected incremental benefit EIB upon varying the willingness-to-pay parameter. For k < k * 9 20 100, EIB < 0 and therefore the status quo is the most cost-effective option. However, if the decision maker is willing to invest a value exceeding the break even point of 20 100, then EIB > 0, which implies that the vaccination becomes the most cost-effective strategy. decision problem. 4 If gathering additional data to supplement the background information D is not an option, the decision maker must choose now whether to keep the standard programme t ¼ 0, or to switch to the new one on the basis of some suitable cost-effectiveness measure of utility (e.g. the net benefit).
However, if deferring the final decision in order first to gather more data is an available option, then the standard intervention t ¼ 0 will typically be maintained while additional evidence E is collected, with the aim of resolving, at least partially, current uncertainty about the parameter h. Once this evidence is available, the analysis can be updated and the utility for each possible intervention will be based on the new posterior density of the parameters of interest, p( t | D, E), which will induce a predictive distribution for some other future outcomes z (generally of the same nature as y). The option of postponing the decision on cost-effectiveness is typically associated with additional sampling costs.
For these reasons, it has been advocated in the literature that health economic evaluations should be subject to some form of Sensitivity Analysis (SA), in order to quantify and qualify the uncertainty underlying the decision process. Formally, SA is defined in risk assessment as the study of 'how uncertainty in some model output can be apportioned, qualitatively or quantitatively, to different sources of uncertainty in the model input'. 26 Various different forms of SA have been recognised in the health economic literature. 8 Marginalisation is implicit in Bayesian decision-theoretic procedures, such as (1); the relevant input can be represented by the value of the parameters of the model, h, whereas the output is the future health economic outcomes on some reference unit. The uncertainty in all the random quantities is accounted for by the computation of the expected utilities used to determine the optimal decision, but is not analysed separately.
The second form of SA is Scenario Analysis (sometimes referred to as Deterministic Sensitivity Analysis, DSA). In this case, the experimenter selects a list of interesting values for (some of) the parameters of the model and evaluates the expected outcomes under all these different scenarios. This procedure is easy to implement when the number of parameters involved is relatively small. However, it fails to consider the possible correlation or the underlying uncertainty about the parameters of interest, only focusing on a set of arbitrarily chosen values, regardless of the likelihood of each of them occurring in reality.
Probabilistic sensitivity analysis
These limitations can be overcome by Probabilistic Sensitivity Analysis (PSA), a procedure in which all input parameters are considered as random quantities and are therefore associated with a probability distribution that describes the state of science (i.e. the background knowledge of the decision maker). This method is in line with the Bayesian analysis, but, instead of being marginalised out, as required by the decision-theoretic analysis, the uncertainty in the parameters is explicitly analysed by means of suitable indicators.
We acknowledge that recently some research has been devoted to PSA to structural uncertainty, 27 which concerns with assuming a probability distribution over a class of possible models (for both parameters and observables) and then produces a result obtained by averaging over the induced posterior distributions. While we reckon that this is a relevant issue, we focus our attention to PSA with respect to parameter uncertainty, i.e. the case in which, given a model, we are concerned with the impact of uncertainty in the parameters on the economic conclusions.
To understand the rationale behind PSA, let us consider a situation in which the information provided by the additional evidence E is so accurate that p(h | D, E) is close to a one-point distribution at the true value: in this case, we shall have effectively learned h. In other words, the uncertainty on the knowledge domain will be totally resolved.
If we then adopt intervention t, the 'known-distribution' expected utility will be Uð t Þ :¼ E½uðY, tÞ j D, E ¼ Z uð y, tÞ pð y j t Þ dy:
Consequently, the overall utility is U * (h) 9 max t U( t ) and we would choose treatment t ¼ 1 if U( 1 ) > U( 0 ), or equivalently if IB(h) > 0, where
is the incremental benefit under parameter-pair h. Note that, similarly to Equation (3), we have
Obviously, in general we shall not be able to learn the value of h with certainty. For this reason, IB(h) and U( t ) remain random quantities, whose current probability distributions are induced by p(h | D).
The idea behind PSA is to compare the actual decision process, based on the analysis of EIB and (2), to the ideal one, characterised by the (currently unknown) quantities computed in equations (5) and (6) . This is done with a view to assessing whether the information provided by the current evidence D is sufficient to take a decision on the optimal treatment, or it would be more effective to defer the final decision until after additional evidence E is collected.
Although analytical methods have also been described, 28, 29 PSA is typically conducted using a simulation approach. 30 For each of a sequence of iterations s ¼ 1,. . ., S, a value h (s) is simulated from the distribution p(h | D). The decision analysis is then conducted using that specific value as if this were the realised one. By means of this procedure, it is possible to produce a sample from the distribution of U( t ), IB(h) or any other related random quantity; the resulting variability in the expected utilities and the influence of each component of h can then be suitably summarised. Table 2 shows the results of the simulation exercise described in Section 3.2. For each of the 1000 iterations, we simulated values for all the parameters (shown in the upper and middle part of Table 2 ) from the distributions defined in Table 1 .
Example (continued)
Considering the net benefit as utility function, we can re-write (5) and (6), respectively, as
and
and use the simulated values for the parameters to calculate the expected utility of option t that would be obtained if the uncertainty on the parameters were resolved to the specific values simulated, which are shown in the lower part of Table 2 .
While this process can be repeated for each value of k, in Table 2 we show again the computations for the reference value of k ¼ 25 000. The last row of the table reports the average values computed over all the simulations of the model, while the last two columns are described in details in Section 6.2.
Summarising the results of PSA
Much of the recent theoretical work has been devoted specifically to the issue of reporting the results of PSA using suitable summary measures. 13, [31] [32] [33] [34] [35] As suggested earlier, while the process of marginalisation performed computing the expected utilities U t provides the 'best' decision given 
Notes: For each iteration, we first simulate a value for the parameters h from the distributions described in Table 1 . These are shown in the upper and mid part of this table. Then (lower part of this table), for each intervention and for each iteration s of the model the induced expected utilities are calculated, according to (8) and (9), and using a fixed value of k ¼ 25 000; for each iteration, the maximum expected utility (i.e. of the optimal intervention) is typeset in italics. The last two columns of the lower part of this table are computed according to (10) and (12) . For each column, the average is computed over the rows (model simulations).
the current data, the essence of PSA is to use the induced distributions for the health economic indicators to qualify the extent to which uncertainty impacts on the decision process. We next review the main indicators used to this end, clarifying the basic differences in their nature.
Cost-effectiveness acceptability curves
In health economic evaluations, it is common to summarise the results of PSA by means of the costeffectiveness acceptability curve (CEAC), 36 defined as CEAC ¼ PrðIBðhÞ 4 0Þ:
If the net benefit is used as utility function, this can be re-expressed as CEAC ¼ Pr(kÁ e À Á c > 0), which depends on the willingness-to-pay parameter k. When EIB > 0, i.e. the optimal decision is treatment 1, this is the probability that learning the value of h (resolving the uncertainty on the parameters) would not change that decision. For the example of Section 2.1, Figure 2 shows the CEAC, again upon varying the value of the parameter k in the range [0; 50000]. For relatively small values of k the probability of 
Cost Effectiveness Acceptability Curve
Willingness to pay Probability of cost effectiveness Figure 2 . PSA by means of the analysis of the CEAC. For each value of the willingness-to-pay parameter k, the CEAC is computed as the proportion of simulations for which IB(h) > 0. Higher values for the CEAC indicate that, for a given budget that the decision maker is willing to invest, the probability that vaccination is in fact more cost-effective than the status quo is large. cost-effectiveness is low, indicating higher uncertainty in the actual cost-effectiveness of the vaccination strategy. For k & 20 000, it reaches a value of 0.5 (when the uncertainty as to what is the most cost-effective intervention is maximum). Figure 2 seems to suggest that, for relatively low values of the willingness-to-pay parameter, there is substantial uncertainty as to whether t ¼ 1 is in fact the optimal intervention; for large values of k, the probability that choosing it is the 'correct' decision is increasingly higher and is 0.53 for k ¼ 25 000. This figure can be deduced from (the complete version of) Table 2 as the proportion of simulations for which IB(h) > 0cf. Equation (6) .
By their very nature, CEACs provide a simple synthesis of the uncertainty about the costeffectiveness of a given intervention 37 and have been widely used in the health economics literature. 8, 9, [38] [39] [40] The main advantage of CEACs is that they allow simple summarisation of the probability of cost-effectiveness upon varying the willingness-to-pay parameter, effectively performing a DSA on k. This circumstance proved to be particularly useful in presenting the results of economic analysis, as decision makers are often not ready to commit to a single value of k (i.e. a single utility function) prior to the analysis being performed.
Despite their wide use, some critical limitations have been pointed out, the main one being that CEACs do not contain a decision rule. For instance, they can only address the problem of how likely it is that resolving parameters uncertainty will change the optimal decision. 41 However, no explicit reference is made to the possible change in the payoffs. More recently, it has been suggested that very different distributions for the IB can produce the same value of the CEAC, which makes it difficult to interpret and might lead to incorrect conclusions for policy makers. 24 Finally, CEACs are concerned only with currently available information, but do not consider explicitly the possibility of gathering additional evidence.
Consequently, by means of CEACs only a partial evaluation of the overall decision process is provided. For this reason, if sensitivity analysis is performed in the context described above (i.e. with the possibility of deferring the decision), then the use of CEACs is clearly not ideal.
The value of information
A purely decision-theoretic approach to PSA, avoiding the shortcomings of CEACs, is based on the VI analysis, 42 an increasingly popular method in health economic evaluations. 4, 41, [43] [44] [45] [46] [47] [48] In this approach, we compare the overall value of the decision process in the ideal scenario, represented by U * (h), to that obtained in the actual evaluation, U * .
The value of obtaining information on h is defined as
which for each value of h quantifies the difference in the utilities produced by the information on the parameters. Again, since the value of U * (h) in general cannot be determined with certainty, we synthesise its distribution considering the expected value of 'perfect' information (EVPI)
where
is the expectation of the overall 'known distribution' utility U * (h). Notice, however, that the additional information that may become available need not be 'perfect'. In other words, we might not be able of learning the value of a parameter perfectly, although new data will generally make our estimation more precise, therefore leading to a less variable posterior distribution. Extensions of this argument are sometimes developed in terms of expected value of sample information, EVSI. 46 If ¼ arg max t U t is the intervention associated with the overall maximum expected utility, for each value of h we can consider
the opportunity loss derived by choosing the alternative associated with the highest overall expected utility, instead of the one associated with the highest known distribution utility. As is easy to see, the average value of OL(h) coincides with the value of EVPI:
While the value of information VI(h) can take on negative values, OL(h) is necessarily nonnegative. Consequently, by a simple application of Jensen's inequality, it can be proved that the EVPI is a non-negative quantity as well.
The EVPI places an upper limit to the amount that we would be willing to pay to obtain any information, perfect or imperfect, about h and, by construction, it measures the weighted average opportunity loss induced by the decision that we make based on the EIB, the weight being the probability of incurring that loss. Therefore, this measure gives us an appropriately integrated indication of: (a) how much we are likely to lose if we take the 'wrong' decision, and (b) how likely it is that we take it, as is easily appreciated using Equations (3) and (7) to re-express Equation (11) as
(the expectations are all taken with respect to the joint distribution of h).
If EIB > 0, then selecting the treatment t ¼ 0 just because (from the analysis of CEAC) there is a large variability in IB(h) will impose unnecessary losses on society, as patients will not benefit from a potentially cost-effective treatment. 25 In contrast, the EVPI analysis provides the decision maker with a rational procedure overcoming this problem. If the large variability in IB(h) is associated with low cost for additional research, then the decision maker can postpone the decision, or perhaps select the treatment t ¼ 1 only for a subset of the population.
The VI analysis is sometimes considered as a separate methodology, which can be performed independently on PSA. However, in our view, for the reasons explained above, it is a fundamental part of the sensitivity analysis process and is in line with the objective of identifying and quantifying the impact of parameters uncertainty on the decision process. Therefore, we view it as the proper method to perform PSA. Figure 3 shows the analysis of the individual (i.e. per patient) expected VI as a function of the willingness-to-pay parameter k for the running example. The EVPI changes its shape around the break even point k ¼ 21 100, since the optimal decision is reversed beyond that threshold.
As the value of k increases from 0, the value of reducing uncertainty becomes increasingly larger. Just after the break even point, it remains almost constant. Even for values of k where there is higher uncertainty in the optimal decision, the absolute magnitude of the patient-specific EVPI is fairly small (compared to the values of the payoffs) in this case. This implies that uncertainty in the parameters does not have a dramatic impact, contrary to what might be suggested by the CEAC analysis (which indicated a probability of cost-effectiveness of 'just' 0.53 for k ¼ 25 000). 
Expected Value of Information
Willingness to pay EVPI Figure 3 . PSA by means of the analysis of the expected VI. For each value of the willingness-to-pay parameter k, the EVPI represents the average OL deriving by using the current most cost-effective intervention, instead of further investigating to reduce the uncertainty in the parameters. Higher values for the EVPI indicate that, for a given budget that the decision maker is willing to invest, the value of additional research is large.
Including a risk aversion parameter in the net benefit
The previous analysis can be extended to consider a more general form for the utility function, to include explicitly the possibility that the decision maker is risk-averse. In this situation, before selecting a new intervention, the decision maker requires lower levels of uncertainty as to whether it will turn out to be the most cost-effective alternative. This has obvious implications on the level and quality of the evidence used to reach the decision.
We consider again the model for the infectious disease presented in Section 2.1, but instead of the simple linear utility function of Equation (4) used so far, we now define a more complex form uð y, rÞ ¼ 1
where r > 0 represents a parameter of risk aversion 22 -the higher the value of r, the more risk-averse the decision maker -and y 9 ke À c now denotes the monetary net benefit. Now, in line with the analysis of Section 5, the quantity that we should investigate for PSA of uncertainty in the parameters, the known distribution utility of Equation (5), has the more complex form
where M Y| t(Àr)9E[exp(ÀrY)] is the moment generating function of the random quantity Y with respect to the distribution p(y | t ), evaluated at the point Àr. Notice that in this case, the utility function is no longer linear in (e, c) and will be in general not straightforward to compute analytically. However, it will typically be available via a simulation approach, such as the MCMC procedure we are using here.
Example (continued)
The incremental benefit is now a function of two parameters, the willingness-to-pay k and the risk aversion r. Figure 4 shows the EIB for various values of r as a function of k, and highlights the important effect on the overall decision process of including the risk propensity of the decision maker. When r ! 0, the decision maker is risk-neutral, and EIB is identical with that based on the monetary net benefit utility function. However, the break even point (i.e. the value of k for which vaccination becomes the best option, producing a positive EIB) does vary upon changing the value of r. As r increases from 0, EIB becomes increasingly non linear. Figure 5 shows the analysis of the EVPI as a function of k and r; again, for r ! 0 we retrieve the same analysis of Figure 3 . When the decision maker's risk-aversion is taken into account, the expected VI becomes generally higher since now the decision maker is less prepared to commit to a given intervention.
While the analysis of the EVPI is appropriately sensitive to the choice of r, it is possible to prove with standard probability calculus that using the utility function of Equation (13) the CEAC is independent of the value of r. This is essential because r is a multiplicative scale parameter and as such, while it does modify the shape of the distributions of IB (and therefore the expected values used to compute the EVPI), it does not affect the probability that IB is positive. Consequently, irrespective of the risk propensity of the decision maker, if PSA is performed using the CEAC the results are the same (and identical with that depicted in Figure 2 ). Again, this feature is not ideal, as we would expect different decision makers with different attitude towards risk to arrive at different results.
Conclusions
We have reviewed the methodology of sensitivity analysis in health economics. Recent years have witnessed the establishment of formal statistical decision-theoretic foundations in this field, along with the increasing awareness of the relevance of monitoring uncertainty in the decision process.
Our standpoint is that PSA is an important component of any health economic analysis; however, we also believe that it should be consistent with the precepts of formal decision-theory, that is it should only concern those aspects that turn out to be crucial in determining the optimal decision. Care should be taken to consider the appropriate context, e.g. whether or not further information could be gathered. 
EIB as a function of the risk aversion parameter
Willingness to pay r→0 r = 0.005 r = 0.02 r = 0.035 Figure 4 . Analysis of the expected incremental benefit including a parameter of risk aversion. For each value of the willingness-to-pay parameter k, we present the EIB for different choices of the risk aversion parameter r. Upon varying this, the shape of the EIB changes significantly, and becomes increasingly non-linear.
Standard methodologies exist that allow the incorporation of risk aversion in the definition of the utility function. These should be exploited to represent more precisely the objectives of public decision makers seeking to identify an optimal strategy. 
EVPI as a function of the risk aversion parameter
Willingness to pay r→0 r = 0.005 r = 0.02 r = 0.035 Figure 5 . PSA by means of the EVPI, accounting for risk aversion. Different choices of r imply a different shape for the EVPI. In particular, the break even point (i.e. the point corresponding to the value of k where the optimal decision changes from the status quo to vaccination) changes for the four scenarios analysed. This is due to the different decision maker's attitude to risk, as specified by r.
